These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 27306805)
1. [Genetic Mutation Accumulation and Clinical Outcome of Immune Checkpoint Blockade Therapy]. Takahashi M Gan To Kagaku Ryoho; 2016 Jun; 43(6):678-82. PubMed ID: 27306805 [TBL] [Abstract][Full Text] [Related]
2. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades]. Okuyama R Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802 [TBL] [Abstract][Full Text] [Related]
3. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy]. Hatae R; Chamoto K Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534 [TBL] [Abstract][Full Text] [Related]
4. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
5. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412 [TBL] [Abstract][Full Text] [Related]
6. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Shin DS; Ribas A Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841 [TBL] [Abstract][Full Text] [Related]
7. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer]. Hamanishi J; Konishi I Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890 [TBL] [Abstract][Full Text] [Related]
8. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747 [TBL] [Abstract][Full Text] [Related]
11. Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies. EBioMedicine; 2016 Nov; 13():1-2. PubMed ID: 27916137 [No Abstract] [Full Text] [Related]
12. Are virus-induced cancers more sensitive to checkpoint inhibitors? Kanaan H; Kourie HR; Awada AH Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334 [No Abstract] [Full Text] [Related]
13. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Hamid O; Carvajal RD Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934 [TBL] [Abstract][Full Text] [Related]
14. [Era of cancer immunotherapy has come]. Nakatsura T Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):164-71. PubMed ID: 27320931 [TBL] [Abstract][Full Text] [Related]
15. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Blank CU Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272 [TBL] [Abstract][Full Text] [Related]
16. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Langer CJ Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885 [TBL] [Abstract][Full Text] [Related]